0
0.5
1
1.5
2+
Hospitalization
74%
Improvement
Relative Risk
Bamlanivimab/e.. Chen et al. EARLY TREATMENT RCT
Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19?
RCT 452 patients in the USA (June - September 2020)
Lower hospitalization with bamlanivimab/etesevimab (p=0.015)
c19early.org
Chen et al., NEJM, October 2020
Favors bamlanivimab/e..
Favors control